Novavax Inc Stock Price, News & Analysis

Novavax (NVAX) announced promising Phase 1 data for its COVID-19 vaccine candidate, NVX-CoV2373, which was generally well-tolerated and exhibited a reassuring safety profile. The trial involved 131 healthy adults aged 18-59 and demonstrated that 100% of participants achieved neutralization titers. Both 5 µg and 25 µg doses generated peak geometric mean titers exceeding 1:3,300. The Matrix-M adjuvant contributed to strong immune responses. The data will be submitted for peer review and available via a preprint server.

On July 23, 2020, Novavax (NASDAQ: NVAX) announced a collaboration with FUJIFILM Diosynth Biotechnologies for the large-scale manufacturing of its COVID-19 vaccine candidate, NVX-CoV2373, following a $1.6 billion funding award from Operation Warp Speed. The production has commenced in Morrisville, North Carolina, with the initial batch for upcoming Phase 3 clinical trials involving 30,000 subjects. The funding will also support clinical development, aiming to deliver 100 million doses by late 2020. Preliminary results from an ongoing Phase 1/2 trial in Australia are expected soon.

Novavax, Inc. (NASDAQ: NVAX) has partnered with FUJIFILM Diosynth Biotechnologies to manufacture bulk drug substance for its COVID-19 vaccine candidate, NVX-CoV2373. This collaboration is part of Novavax’s $1.6 billion funding from the U.S. government’s Operation Warp Speed, aimed at providing millions of vaccine doses by late 2020. Initial production has begun at FUJIFILM’s North Carolina facility, supporting a pivotal Phase 3 clinical trial expected to start in fall 2020. The vaccine is based on proprietary nanoparticle technology and aims to demonstrate safety and efficacy through extensive trials.

Novavax, Inc. (NASDAQ: NVAX) announced that Gregory M. Glenn, M.D. will present on the progress of NVX-CoV2373, its COVID-19 vaccine candidate, at the 2nd International Society for Vaccines Virtual Congress on July 21, 2020, at 9:55 a.m. ET. The NVX-CoV2373 vaccine is designed using recombinant nanoparticle technology and is funded by the U.S. Government with up to $1.6 billion through Operation Warp Speed. The Phase 1 clinical trial commenced in May 2020, with preliminary results expected in July 2020.

Novavax, Inc. (Nasdaq: NVAX) announced its selection for Operation Warp Speed, receiving a $1.6 billion award to advance its COVID-19 vaccine, NVX-CoV2373. This funding will support late-stage clinical trials, including a pivotal Phase 3 trial with up to 30,000 subjects, and large-scale manufacturing of 100 million doses. Preliminary safety results from a Phase 1/2 trial are expected by late July 2020, with additional support from CEPI amounting to $388 million. This partnership aims to expedite vaccine delivery amid the COVID-19 pandemic.

Novavax, Inc. (NASDAQ: NVAX) announced the appointment of Frank Czworka as Senior Vice President, Global Sales, and the promotion of Brian Webb to Senior Vice President, Manufacturing. Czworka, with over 20 years of experience, has previously held senior roles in biopharmaceutical sales and marketing. Webb has been instrumental in expanding manufacturing capabilities. The company aims to advance its COVID-19 vaccine candidate, NVX-CoV2373, and its quadrivalent influenza nanoparticle vaccine, NanoFlu, to the market, intending to positively impact global health.

Novavax (NASDAQ: NVAX) announced the appointment of Ben Machielse as Executive Vice President, CMC, on June 29, 2020. Machielse will oversee manufacturing and regulatory functions as the company advances its COVID-19 vaccine candidate, NVX-CoV2373. Other leadership promotions include John Trizzino as Chief Business Officer and CFO, John Herrmann III as Chief Legal Officer, and Jill Hoyt as Chief Human Resources Officer. Novavax is ramping up its manufacturing capacity for its vaccines, which include NVX-CoV2373 and NanoFlu, with clinical trial results expected soon.

Novavax, a biotechnology company focused on vaccines, will have its Chief Business Officer, John J. Trizzino, participate in the H.C. Wainwright Virtual Fireside Chat on June 25, 2020, at 10:00 a.m. ET. The discussion will center on Novavax's COVID-19 vaccine candidate, NVX-CoV2373. This candidate is part of Novavax's broader mission to develop innovative vaccines, including the NanoFlu™, which recently succeeded in a Phase 3 trial. More insights can be found on Novavax's website.

Novavax, Inc. (NASDAQ: NVAX) has appointed David Mott as an independent director of its Board, enhancing its leadership team with his extensive experience in biopharmaceuticals. Mott, who recently acquired nearly 65,000 shares of Novavax, brings over 30 years of management and investment expertise. His appointment comes as Novavax ramps up efforts in developing its COVID-19 vaccine (NVX-CoV2373) and prepares for regulatory submissions for NanoFlu™. Mott will also serve on the Compensation Committee, aiming to support the company's mission against serious infectious diseases.